T1	intervention 14 42	Abemaciclib Plus Fulvestrant
T2	outcome 2956 2965	median OS
T3	outcome 2507 2541	Time to second disease progression
T4	iv-cont-median 2551 2562	23.1 months
T5	cv-cont-median 2566 2577	20.6 months
T6	outcome 2580 2600	time to chemotherapy
T7	iv-cont-median 2610 2621	50.2 months
T8	cv-cont-median 2625 2636	22.1 months
T9	outcome 2643 2669	chemotherapy-free survival
T10	iv-cont-median 2679 2690	25.5 months
T11	cv-cont-median 2694 2705	18.2 months
T12	outcome 1964 1970	deaths
T13	outcome 2074 2083	median OS
T14	iv-cont-median 2087 2098	46.7â€‰months
T15	cv-cont-median 2136 2147	37.3 months
T18	total-participants 1712 1715	669
T19	intervention-participants 1732 1735	446
T20	control-participants 1835 1838	223
T21	control 1901 1925	placebo plus fulvestrant
T22	outcome-Measure 1600 1616	Overall survival
T23	outcome-Measure 1573 1598	progression-free survival
T16	outcome 2333 2356	more pronounced effects
T17	outcome 2442 2472	primary resistance to prior ET
T24	outcome 2374 2404	patients with visceral disease
T25	outcome 2800 2814	safety signals
